Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PathoGenesis
Seattle, Washington, United States
- Ownership
- Private
- Employees
- ~275
- Development stage
- Other
01
Overview
PathoGenesis developed TOBI (tobramycin) inhalation solution, an antibiotic approved for managing chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients. The product was successfully commercialized before the company's acquisition, with annual sales exceeding $60 million in 1999. The company also had a preclinical program in tuberculosis.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Small moleculeAntibiotic
- Industry
- Biotech
Beyond the preview
Go deeper on PathoGenesis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PathoGenesis.